Treating now vs. post transplant

Similar documents
HCV Management in Decompensated Cirrhosis: Current Therapies

Treatment of Unique Populations Raymond T. Chung, MD

Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos

Saeed Hamid, MD Alex Thompson, MD, PhD

HCV In 2015: Maximizing SVR

Expert Perspectives: Best of HCV from EASL 2015

Antiviral treatment in HCV cirrhotic patients on waiting list

Hepatitis C in Special Populations

Treating HCV After Liver Transplantation: What are the Treatment Options?

HCV-G3: Sofosbuvir with ledipasvir or daclatasvir?

Hepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona

Why make this statement?

Approved regimens for cirrhotic patients

Treatment of Hepatitis C Recurrence after Liver Transplantation. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona

HCV Treatment in 2016

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of

TREATMENT OF GENOTYPE 2

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

DAAs in the era of decompensated liver disease. Piero L. Almasio University of Palermo

Update on chronic hepatitis C treatment: current trends, new challenges, what next?

Experience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona

DAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France

VIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015

IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?

10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection

A treatment revolution: current management for chronic HCV

HCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland

Recurrent HCV after a Pre-LTx Course of SOF/DAC:

Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany

IFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster

What Should We Do With Difficult to Treat HCV Populations?

Genotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty

TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona

Treatments of Genotype 2, 3,and 4: Now and in the future

The ASTRAL Program Abstracts LB-2, LB-12, 205, 209

HCV Therapy in Liver Transplant Candidate

Learning Objective. After completing this educational activity, participants should be able to:

Treating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona

Pivotal New England Journal of Medicine papers 2014 Phase 3 Trial data

How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France

The HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)

SOLAR-1 (Cohorts A and B)

Rome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING

HEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation

What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago

HCV Treatment of Genotype 1: Now and in the Future

10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives

Baseline and acquired viral resistance to DAAs: how to test and manage

4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA

Failure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016

Next generation DAAs: Combining efficacy and safety profile. Jiannis Vlachogiannakos

HCV TREATMENT PRE- AND POST TRANSPLANTATION

Case 2: A 71-year-old man with cirrhosis

Future strategies with new DAAs

Transformation of Chronic Hepatitis C Treatment

Treatment of recurent hepatitis infection after liver transplantation

Update in the Management of Hepatitis C: What Does the Future Hold

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors

SOLAR-1 (Cohorts A and B)

ICVH 2016 Oral Presentation: 28

Initial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona

Associate Professor of Medicine University of Chicago

Hepatitis C Highlights from ILC / EASL 2016

Management of HCV in Decompensated Liver Disease

Dr. Siddharth Srivastava

Evolution of Therapy in HCV

Patients with compensated cirrhosis: how to treat and follow-up

HCV: Current SOTA of Management of Treatment Experienced Patients

A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran

Viva La Revolución: Options to Combat Hepatitis C

HCV care after cure. This program is supported by educational grants from

Latest Treatment Updates for GT 2 and GT 3 Patients

STATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD

Treatment of HCV in 2016

HCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London

47 th Annual Meeting AISF

Addressing Unmet Medical Needs in HCV Genotype 3

HCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD

How to improve the access to therapy in South and East: Romania. Mihai Voiculescu. Romania

VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES

Management of HCV Tawesak Tanwandee

CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015

Need to Assess HCV Resistance to DAAs: Is it Useful and When?

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Summary from AASLD 2014 for Hepatitis C Boston 7-11 November 2014

HIV/Hepatitis C in France: data from real life cohorts LIONEL PIROTH CHU DIJON UNIVERSITY OF BURGUNDY DECEMBER LONDON

Patients with Cirrhosis: Managing the HCV Peri-Transplant Patient

HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London

Rapid Response from San Francisco: The Latest in the HCV Treatment Revolution

2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients

Hepatitis C Treatment 2014

HEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA

8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV

Disclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH

Will difficult-to-treat patients remain difficultto-treat. generation of treatments?

Introduction. The ELECTRON Trial

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Update on Real-World Experience With HARVONI

Transcription:

Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence Few drug drug interactions Cons if treated pre transplant Progression despite SVR Decreased response rates in advanced fibrosis/cirrhosis Longer duration for some Toxicity? Risk of decompensation Sudden progression Health costs advanced disease? Post transplant recurrent disease easily treated

Scrutinising results in cirrhosis Comparative results in patients with advanced cirrhosis Safety Resistance Retreatment options Pharmacokinetics Overall evidence decision

SVR12: Absence of Cirrhosis vs Cirrhosis GT 1 Treatment-Experienced (ION-2) Afdhal et al NEJM 2014 Absence of Cirrhosis Cirrhosis SVR12 (%) 83/87 19/22 89/89 18/22 86/87 22/22 88/89 22/22 LDV/SOF LDV/SOF + RBV LDV/SOF LDV/SOF + RBV 12 Weeks 24 Weeks Error bars represent 95% confidence intervals. 4

ALLY-1: DCV, SOF + RBV combination for HCV patients with advanced cirrhosis or post-transplant recurrence SVR12 by Child-Pugh class: Advanced cirrhosis cohort, all genotypes SVR12 (%) 11/ 12 30/ 32 9/ 16 A B C 21/ 29/ 22/ 28/ 10/ 30/ 10/ 23 37 23 37 11 31 18 No Yes No Yes >3.5 <2.8 2.8 3.5 41/ 6/ 3/ 33/ 9/ 8/ 49 8 18 37 12 11 <1.7 >2.3 <2.0 >3.0 1.7 2.3 2.0 3.0 Child-Pugh class Ascites HE Albumin g/dl Post-transplant results similar to SOLAR trials CP C patients have reduced SVR secondary to relapse of unclear mechanism Effect on long-term outcomes critical to make decision of whether to treat CP C Poordad F, et al. EASL 2015, Vienna. #LO8 INR Total bilirubin mg/dl

LDV/SOF + RBV for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study Flamm SL, et al. AASLD 2014, Boston. #239 Charlton Gastroenterology 2015 Wk 0 Wk 12 Wk 24 Wk 36 LDV/SOF + RBV SVR12 LDV/SOF + RBV SVR12 SVR12 G1 and 4, CPT Class B and C 108 patients randomized 1:1 to 12 or 24 weeks of treatment G1 or 4 tx-naïve or experienced patients with decompensated cirrhosis CPT class B (7 9) or C (score 10 12) SVR12 (%) 3 relapses 1 relapse 1 death 2 deaths 1 relapse 1 death 1 relapse 1 LTFU 1 death 45/52 42/47 Overall 26/30 24/27 19/22 18/20 CPT B CPT C LDV/SOF + RBV 12 wks LDV/SOF + RBV 24 wks

DCV + SOF in G1 monoinfected patients from French observational cohort ANRS CO22 HEPATHER Real-world French database 409 pts treated with DCV + SOF ± RBV RBV n=92; no RBV n=317 78% cirrhosis; 75% TE SVR4 (%) 27/ 31 19/ 23 47/ 53 203/ 210 4/ 4 8/ 8 14/ 14 65/ 66 Pts (%) 46/ 54 45/ 53 250/ 263 172/ 184 12/ 12 11/ 11 79/ 80 61/ 62 SVR4 (%) 20/ 20 26/ 34 47/ 47 203/ 216 3/ 3 9/ 9 18/ 18 59/ 60 Factors associated with failure: No RBV 12-week duration Cirrhosis Pol S, et al. EASL 2015, Vienna. #LO3 100% SVR for non-cirrhotics with all regimens Without RBV, 24 weeks better than 12 for cirrhotics RBV may eliminate need for extra 12 wks (as for LDV/SOF) Authors recommended 12 wks DCV + SOF + RBV

regimens containing SOF ± SMV in the TRIO network: Academic and community treatment of a real-world, heterogeneous population VR12 G1, ITT population All Treatment-naive Treatment-experienced Cirrhotic G1 (All) 273/353 263/317 164/205 126/151 109/147 137/166 54/79 110/144 G1a 186/240 163/200 117/147 79/98 69/92 84/102 35/53 67/92 G1b 64/84 77/88 37/45 39/42 27/39 38/46 17/21 31/37 SOF + PEG + RBV SMV + SOF ± RBV Dieterich D, et al. EASL 2015, Vienna. #P0775 Both regimens performed less well than in clinical trials in cirrhosis pts G1a performed less well than G1b PR/SOF performed well in treatment failure non-cirrhotic at 74% as predicted by FDA

SVR12 (%) BOSON: SOF + PEG-IFN/RBV for 12 weeks vs SOF + RBV for 16 or 24 weeks in G3 HCV-infected patients and treatmentexperienced cirrhotic G2 patients SVR12 in G3 by treatment history and cirrhosis status 58/70 65/72 68/71 12/21 18/2294/112 21/2 83/100 41/54 44/54 49/52 10/11 17/36 26/34 30/35 3 No cirrhosis Cirrhosis No cirrhosis Cirrhosis Treatment-naive Treatment-experienced SOF + RBV 16 weeks SOF + RBV 24 weeks SOF + PEG/RBV 12 weeks SOF treatment emergent variants L159F and V321A were observed in 9/78 (12%) pts: Peg-IFN RBV with SOF still a treatment L159F was present at baseline and at the option for G3 time of virologic failure in 1 patient, and only 16 week SOF + RBV for G3 did not at the time of virologic failure in 6 patients meet expectation Newer DAAs with activity against G3 still a necessity V321A emerged at the time of Foster virologic GR, et al. EASL failure 2015, in Vienna. 2 patients #LO5

Daclatasvir (DCV) + sofosbuvir (SOF) ± ribavirin (RBV) in G3 patients: Interim analysis of a French multicenter compassionate use program 601 G3 pts received: DCV + SOF for 12 wks (4%) DCV + SOF + RBV for 12 wks (17%) DCV + SOF for 24 wks (15%) DCV + SOF + RBV for 24 wks (64%) Patients: F3 / extrahepatic manifestations / post-lt HCV recurrence / indication for liver or kidney transplant Mostly male (75%), mono-infected (83%), cirrhotic (77%), treatment-experienced (73%) Median BL platelets 118.5 x 109/L Median BL albumin 39.0 g/l Hezode C, et al. EASL 2015, Vienna. #LP05 Patients (%) SVR4 11/12 5/6 22/29 52/59 d/c related to AEs (1 pt), death (2 pts), patient decision (1 pt) 12-week regimen effective for non-cirrhotic G3 pts Cirrhotics appear to benefit from 24 weeks Effect of RBV not included in analysis

Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks SOF + NS5A inhibitors ± RBV is effective in HCV G1 and G3 SVR12 rate % (ITT) Age <65 100 80 60 40 20 0 80 71 74 73 Harmed SAE/MELD worse by Age 2 >65 Helped Foster GR, et al. MELD EASL 2015, improved Vienna. by #O002 2 SVR12 by genotype and regimen p<0.05 86 81 82 70 71 60 59 43 252 28 172 15 164 21 45 5 All G1 Risk:Benefit N (%) Albumin >35 Albumin <35 Harmed SAE/MELD worse by 14 (14%) 94 (33%) 2 Helped MELD improved by 2 29 (28%) 53 (18%) Total 102 288 9 (32%) 14 (33%) 4 (14%) 6 (14%) Total 28 43 61 7 114 7 G3 89 SOF/LDV/RBV SOF/LDV 85 100 27 13 3 Others SOF/DCV/RBV SOF/DCV Restricted regimen: 12 weeks SOF only Encouraging results in G1 somewhat concerning G3 G3 SVR favored by SOF + DCV vs SOF + LDV, compared with EC 50 s Estimates of risk benefit may

Safety and effectiveness of SOF-based regimens for the treatment of HCV G3 and 4 infections: Interim analysis of a prospective, observational study SVR12 SVR12 among G3, SOF/R 16/ 18 87/ 113 19/ 22 3/7 12/ 12 4/4 22/ 50 17/ 23 18/ 23 30/ 37 G3 G4 G4 is more effectively treated with 2 oral DAAs G3 treatment with SOF/RBV was less effective in real-world TE cirrhosis only 44% SVR Markers of advanced liver disease (MELD, albumin, platelet count) predictive of SVR Alqahtani S, et al. EASL 2015, Vienna. #P0840 Relapse among G3, SOF/R 26/ 50 4/23 4/23 6/37

Integrated safety analysis of SOLAR 1 and 2: LDV/SOF + RBV in >600 decompensated and post-lt patients with HCV infection Pretransplant CP B + C n=215 20 (9%) d/c treatment 9 adverse events 4 deaths 7 liver transplants 195 completed treatment Randomized N=660 F0 F3 and CP A n=330 11 (3%) d/c treatment 5 adverse events 1 death 1 investigator discretion 2 non-compliance 1 lost to follow-up 1 withdrew consent 319 completed treatment Samuel D, et al. EASL 2015, Vienna. #P0774 Post-transplant CP B and C* n=114 11 (10%) d/c treatment 5 adverse events 3 deaths 2 investigator discretions 1 protocol violation 103 completed treatment Treatment-emergent deaths Populatio n Did not complete treatment Septic shock Pre CP B Cardiac arrest in setting of sepsis Pre CP B Oliguric renal failure Pre CP C Septic shock Pre CP C GI bleeding and liver failure Pre CP C Multi-organ failure and septic shock Pre CP C Cardiac arrest due to ischemic heart disease Pre CP C Staphylococcus aureus sepsis Pre CP C GI bleeding & liver failure Post CP A Progressive multifocal leukoencephalitis Post CP A Thoracic aorta aneurysm dissection Post CP B Internal bleeding Post CP B Multi-organ failure with sepsis Post CP B Multi-organ failure due to decompensated cirrhosis Post CP B Infiltrative multifocal hepatocarcinoma Post CP C Intestinal ischemia Post CP C Died 30 days after completing treatment Sepsis and multi-organ failure Pre CP B Liver failure due to chronic liver F0 Post rejection F3 Myocardial infarction Post CP A

HCV-TARGET: Safety and efficacy of SOF-containing regimens in HCV-infected patients with reduced renal function Dichotomous = n (%) Continuous = mean (range) Early High treatment rates discontinuation of SVR independent of baseline renal AEfunction In patients with egfr <30 worsening renal function Saxena V, et al. EASL 2015, Vienna. #LP08 Safety outcomes by baseline egfr egfr 30 n=17 egfr 31 45 n=56 egfr 46 60 n=157 egfr >60 n=1559 Common AEs Fatigue 3 (18) 19 (34) 56 (36) 543 (35) Headache 1 (6) 9 (16) 19 (12) 274 (18) Nausea 3 (18) 8 (14) 33 (21) 247 (16) Anemia AE 6 (35) 16 (29) 37 (24) 246 (16) Required transfusion(s) 2 (12) 5 (9) 3 (2) 31 (2) Erythropoietin start on 1 (6) 8 (14) 14 (9) 50 (3) treatment RBV Reduction in RBV due to 3 (38) 8 (30) 33 (42) 185 (19) anemia RBV discontinuation 0 (0) 4 (15) 1 (1) 12 (1) Worsening renal function 5 (29) 6 (11) 4 (3) 14 (1) Renal or urinary system AEs 5 (29) 6 (11) 13 (8) 84 (5) Any serious AEs 3 (18) 13 (23) 8 (5) 100 (6) Cardiac serious AEs 1 (6) 2 (4) 8 (5) 53 (3) Early treatment discontinuation 1 (6) 4 (6) 6 (4) 68 (4) More anemia and more monitoring with SOFcontaining regimen 1 (6) 2 (3) 4 (2) 39 (3) Death 1 (6) 0 (0) Does not validate 2 (1) safety of DAA utilization 10 (1)

hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension Median total albumin and bilirubin at baseline and follow-up Week 4 (all pts, N=96) (12.4) p<0.0001 p<0.0001 Median total albumin (g/dl) Normal range total albumin: 3.3 4.9 g/dl Median total bilirubin (mg/dl) Normal range total bilirubin: 0.2 1.2 mg/dl 0 Baseline f/u 4 Baseline f/u 4 Arms 1 and 2: HVPG change over observation and 48-week treatment periods Arm 1 Wk/ Arm 2 Wk Observation /0 Start treatment 0/24 End treatment 48/72 Observation period (Arm 2; n=18) Afdhal N, et al. EASL 2015, Vienna. #LP13 Treatment period (n=37) Baseline (n=37) EOT (n=37)

hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension ms 1 and 2: HVPG % change after treatment in subset of patients with baseline HVPG 12 mm H Patients with >20% decrease (8/33) * * * * n=2 Baseline MELD score <10 10 *Patients with HVPG 12 mm Hg at end of treatmen SOF + RBV for 48 weeks: SVR rate of 72% Clinical improvement occurs after viral suppression more rapidly than remodeling of fibrosis and reduction in HVPG Effect of SVR12 and long-term viral suppression/cure on HVPG may manifest later, and is being explored in these patients 1 year post-treatment Afdhal N, et al. EASL 2015, Vienna. #LP13

PK and safety of co-administered ABT-450/r, ABT-267 and ABT-333 as a single dose in subjects with normal hepatic function and in subjects with mild, moderate, and severe hepatic impairment Mild impairment: ABT-450, -333 and -267 exposures not clinically significantly different (AUCs up to ±30% different) Moderate impairment: ABT-333 and -267 exposures not clinically significantly different (AUCs 30% lower), ABT-450 exposures moderately higher (AUC 62% higher) Severe impairment: ABT-450 and -333 exposures significantly higher ABT-450 ABT-333 ABT-267 Ritonavir

The prevalence and effect of HCV NS5A resistanceassociated variants in subjects with compensated cirrhosis treated with LDV/SOF ± RBV SVR12 rates by resistance level of baseline NS5A RAVs Treatment-naive G1a Treatment-experienced SVR12 (%) 11/12 3/3 70/70 10/15 11/11 187/193 Treatment-naive G1b Treatment-experienced 15/16 5/5 54/54 19/20 11/11 96/100 Sarrazin C, et al. EASL 2015, Vienna. #P0773 NS5A RAVs important in G1 treatment-failure cirrhotics RBV, not duration, overcomes effective NS5A RAVs on

Urgent lessons to be learned from DAA IFN free therapy in decompensated cirrhosis What degrees of cirrhosis impair response? What is the optimal duration of therapy for different stages of cirrhosis? Is mortality less than expected in this population Is the long term outcome better in Child Pugh C when treated pre transplant? What are the consequences of relapse? Are pre-existent resistant variants more critical in this group? Are there higher rates of adverse events in patients with decompensated cirrhosis? To what degree is disease reversible? Is the natural history of the disease altered? Is mortality lessened in this group